Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting 1 in 500 individuals. It is characterized by unexplained myocardial hypertrophy with the underlying pathology of myofibrillar disarray and interstitial fibrosis. Complications of this disease include sudden cardiac death due to ventricular tachyarrhythmias and heart failure, both of which may be related, at least in part to the underlying fibrosis in the myocardium.
A 22-year-old male presented in 2012 to the UVA Hypertrophic Cardiomyopathy (HCM) Center of Excellence after being previously diagnosed with suspected HCM after a routine sports physical. At the time of evaluation, he was otherwise asymptomatic without a history of shortness of breath, chest pain, orthopnea, palpitations, or syncope. Of note, family history revealed a maternal uncle who suffered sudden cardiac death in his 50's. Physical examination revealed a mid to late systolic murmur with a grade of 1/6, with intensity increasing with Valsalva [1] [2] [3] [4] [5] .
EKG showed sinus rhythm and left ventricular hypertrophy by voltage criteria with secondary repolarization abnormalities. Transthoracic echocardiogram (TTE) demonstrated moderate asymmetric septal hypertrophy with normal LV cavity size and ejection fraction of 75% with, mild mitral regurgitation and systolic anterior motion (SAM), but no significant outflow gradient. Exercise stress testing was unremarkable. Holter monitor showed sinus rhythm with no premature ventricular contractions and rare premature atrial contractions. No high grade tachycardia or bradycardia arrhythmias were recorded. Genetic testing revealed no known clinically significant variants in the common genes linked to HCM. CMR showed asymmetric septal hypertrophy with a septal:posterior wall ratio of 1.6:1, SAM, and mild mitral regurgitation. No evidence of late gadolinium enhancement (LGE) was identified (Figure1A-B). In 2014, 2 years after his initial visit and CMR, he was enrolled in the HCMR study [6] and underwent a research CMR where evidence of LGE in the RV insertion sites was noted (Figure1C-D).
Discussion
HCM is generally caused by mutations in genes that encode cardiac sarcomere proteins that are most commonly inherited in an autosomal dominant fashion. Patients diagnosed at a younger age tend to have a higher risk of sudden cardiac death whereas patients diagnosed later in life tend to have comparable mortality to the general public [7] .
Although echocardiography is the typical method used for screening and diagnosis, CMR has emerged as the gold standard for imaging morphology and fibrosis with both LGE (replacement fibrosis) and T1 mapping (interstitial fibrosis) [8] . The presence of LGE has been associated with cardiac death. There is growing evidence that the extent of LGE corresponds to the risk of SCD [3] . Effective risk stratification is vital for identifying the patients that would benefit most from an implantable cardioverter defibrillator to prevent fatal ventricular arrhythmias.
This particular case highlights the early development and progression of LGE in a young patient. Two previous studies have documented progression of LGE in patients [4, 5] but the patients were much older on average. The study by Todiere et al demonstrated that of 55 HCM patients with a mean age of 43±18 at baseline, 45 had some LGE [4] . Of the 10 that had none, 8 developed LGE over the ensuing 2 years. In the study by Choi et al, the mean age was even higher (59 ± 13) and the prevalence of LGE was 91.5% at the first CMR. While there are no current guidelines for serial CMR studies in HCM, the reported case shows that progression from no to some fibrosis is possible over a relatively short time frame such as 2 years and the transition from no fibrosis to some fibrosis may occur in the early 20's. Tracking progression of fibrosis in patients with HCM could shed further light on the natural history of this disease and the potential relationship to adverse events.
